Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thymopeptides are a mixture of polypeptides extracted from the thymus gland, typically of porcine or bovine origin, that serve as immunomodulators. They function by promoting the maturation, differentiation, and activation of T-lymphocytes, thereby enhancing the body's cellular immune response. In clinical practice, particularly in China, thymopeptides are utilized for the treatment of various conditions associated with immune dysfunction, including chronic hepatitis B, primary or secondary immunodeficiency diseases, and as an adjuvant therapy in cancer treatment. The drug is currently being investigated in clinical trials, such as ChiCTR2500108177, for its efficacy in treating oral leukoplakia, where it is administered as enteric-coated tablets to modulate the local immune environment and potentially prevent malignant transformation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thymopeptides.